{"filing":{"accession_number":"0001437749-26-031389","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"crvo20260928_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926031389/crvo20260928_8k.htm"},"events":[{"id":35506,"run_id":32705,"accession_number":"0001437749-26-031389","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CervoMed announced pharmacokinetic, regulatory, and manufacturing advances for its lead drug candidate neflamapimod, including a new 50 mg tablet formulation with improved PK profile, FDA removal of a prior drug exposure limit, and a controlled manufacturing process that enable advancement of a higher-dose 100 mg twice-daily regimen in future clinical trials.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39574,"accession_number":"0001437749-26-031389","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced pharmacokinetic, regulatory, and manufacturing advances for its lead drug candidate neflamapimod, including a new 50 mg tablet formulation with improved PK profile, FDA removal of a prior drug exposure limit, and a controlled manufacturing process. These developments enable advancement of a higher-dose 100 mg twice-daily regimen in future clinical trials. While this is a clinical-stage biotech company's operational and regulatory milestone rather than a discrete event type (not an earnings release, M\u0026A activity, or executive change), the announcement materially affects the development trajectory and regulatory pathway of the company's lead program, which would be material to investors assessing the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:10:36.675619+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39575,"accession_number":"0001437749-26-031389","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced pharmacokinetic results for a new neflamapimod 50 mg tablet formulation, FDA removal of a prior drug exposure limit, and a controlled manufacturing process. These are material operational and regulatory milestones for a clinical-stage biotech company advancing its lead drug candidate, but they do not constitute a discrete event type (not earnings, M\u0026A, litigation, impairment, etc.). The disclosure centers on formulation improvements, regulatory clearance, and manufacturing advances that reduce clinical and manufacturing risk—core operational developments for a drug development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:10:36.675619+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39574,"accession_number":"0001437749-26-031389","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced pharmacokinetic, regulatory, and manufacturing advances for its lead drug candidate neflamapimod, including a new 50 mg tablet formulation with improved PK profile, FDA removal of a prior drug exposure limit, and a controlled manufacturing process. These developments enable advancement of a higher-dose 100 mg twice-daily regimen in future clinical trials. While this is a clinical-stage biotech company's operational and regulatory milestone rather than a discrete event type (not an earnings release, M\u0026A activity, or executive change), the announcement materially affects the development trajectory and regulatory pathway of the company's lead program, which would be material to investors assessing the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:10:36.675619+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-09-28"},{"id":39575,"accession_number":"0001437749-26-031389","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced pharmacokinetic results for a new neflamapimod 50 mg tablet formulation, FDA removal of a prior drug exposure limit, and a controlled manufacturing process. These are material operational and regulatory milestones for a clinical-stage biotech company advancing its lead drug candidate, but they do not constitute a discrete event type (not earnings, M\u0026A, litigation, impairment, etc.). The disclosure centers on formulation improvements, regulatory clearance, and manufacturing advances that reduce clinical and manufacturing risk—core operational developments for a drug development program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T21:10:36.675619+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-09-28"}]}